MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.eclinm.2023.101920

Медицинская библиотека · EClinicalMedicine · 2023

High-dose ubiquinol supplementation in multiple-system atrophy: a multicentre, randomised, double-blinded, placebo-controlled phase 2 trial.

Mitsui Jun, Matsukawa Takashi, Uemura Yukari, Kawahara Takuya, Chikada Ayaka, Porto Kristine Joyce L, Naruse Hiroya, Tanaka Masaki, Ishiura Hiroyuki, Toda Tatsushi, Kuzuyama Haruko, Hirano Mari, Wada Ikue, Ga Toshio, Moritoyo Takashi, Takahashi Yuji, Mizusawa Hidehiro, Ishikawa Kinya, Yokota Takanori, Kuwabara Satoshi, Sawamoto Nobukatsu, Takahashi Ryosuke, Abe Koji, Ishihara Tomohiko, Onodera Osamu, Matsuse Dai, Yamasaki Ryo, Kira Jun-Ichi, Katsuno Masahisa, Hanajima Ritsuko, Ogata Katsuhisa, Takashima Hiroshi, Matsushima Masaaki, Yabe Ichiro, Sasaki Hidenao, Tsuji Shoji

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Functionally impaired variants of COQ2, encoding an enzyme in biosynthesis of coenzyme Q10 (CoQ10), were found in familial multiple system atrophy (MSA) and V393A in COQ2 is associated with sporadic MSA. Furthermore, reduced levels of CoQ10 have been demonstrated in MSA patients.

METHODS

This study was a multicentre, randomised, double-blinded, placebo-controlled phase 2 trial. Patients with MSA were randomly assigned (1:1) to either ubiquinol (1500 mg/day) or placebo. The primary efficacy outcome was the change in the unified multiple system atrophy rating scale (UMSARS) part 2 at 48 weeks. Efficacy was assessed in all patients who completed at least one efficacy assessment (full analysis set). Safety analyses included patients who completed at least one dose of investigational drug. This trial is registered with UMIN-CTR (UMIN000031771), where the drug name of MSA-01 was used to designate ubiquinol.

FINDINGS: Between June 26, 2018, and May 27, 2019, 139 patients were enrolled and randomly assigned to the ubiquinol group (n = 69) or the placebo group (n = 70). A total of 131 patients were included in the full analysis set (63 in the ubiquinol group; 68 in the placebo group). This study met the primary efficacy outcome (least square mean difference in UMSARS part 2 score (-1.7 [95% CI, -3.2 to -0.2]; P = 0.023)). The ubiquinol group also showed better secondary efficacy outcomes (Barthel index, Scale for the Assessment and Rating of Ataxia, and time required to walk 10 m). Rates of adverse events potentially related to the investigational drug were comparable between ubiquinol (n = 15 [23.8%]) and placebo (n = 21 [30.9%]).

INTERPRETATION: High-dose ubiquinol was well-tolerated and led to a significantly smaller decline of UMSARS part 2 score compared with placebo.

FUNDING: Japan Agency for Medical Research and Development.

Для цитирования: Mitsui Jun, Matsukawa Takashi, Uemura Yukari, Kawahara Takuya, Chikada Ayaka, Porto Kristine Joyce L, Naruse Hiroya, Tanaka Masaki, Ishiura Hiroyuki, Toda Tatsushi, Kuzuyama Haruko, Hirano Mari, Wada Ikue, Ga Toshio, Moritoyo Takashi, Takahashi Yuji, Mizusawa Hidehiro, Ishikawa Kinya, Yokota Takanori, Kuwabara Satoshi, Sawamoto Nobukatsu, Takahashi Ryosuke, Abe Koji, Ishihara Tomohiko, Onodera Osamu, Matsuse Dai, Yamasaki Ryo, Kira Jun-Ichi, Katsuno Masahisa, Hanajima Ritsuko, Ogata Katsuhisa, Takashima Hiroshi, Matsushima Masaaki, Yabe Ichiro, Sasaki Hidenao, Tsuji Shoji. High-dose ubiquinol supplementation in multiple-system atrophy: a multicentre, randomised, double-blinded, placebo-controlled phase 2 trial.. EClinicalMedicine. 2023. DOI: 10.1016/j.eclinm.2023.101920.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.